Lupenox is not low-quality; to the contrary, it probably works as well as any other low-molecular-weight heparin drug in the medical indications where such drugs are used. If a company submitted a Lupenox NDA (rather than an ANDA), it could likely obtain FDA approval for Lupenox as a new branded drug.
But the topic of this discussion is not a new branded drug—it’s an application to the FDA for a generic version of Lovenox. For this, merely being a safe and effective LMWH drug is not sufficient; to be approved, the drug in question must satisfy the FDA’s requirements for sameness to branded Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.